[1]吴蔚 何敏 李益明.下丘脑垂体疾病对糖脂代谢的影响[J].国际内分泌代谢杂志,2022,42(01):2-6,11.[doi:10.3760/cma.j.cn121383-20220117-01034]
　Wu Wei,He Min,Li Yiming..Effects of hypothalamic and pituitary diseases on glucose and lipid metabolism[J].International Journal of Endocrinology and Metabolism,2022,42(01):2-6,11.[doi:10.3760/cma.j.cn121383-20220117-01034]
点击复制

下丘脑垂体疾病对糖脂代谢的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年01期
页码:
2-6,11
栏目:
专家论坛
出版日期:
2022-01-20

文章信息/Info

Title:
Effects of hypothalamic and pituitary diseases on glucose and lipid metabolism
作者:
吴蔚 何敏 李益明
复旦大学附属华山医院内分泌科 200040
Author(s):
Wu Wei;  He Min;  Li Yiming.
Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai 200040, China
关键词:
糖脂代谢;  代谢综合征;  下丘脑垂体疾病
Keywords:
Glucose and lipid metabolism;  Metabolic syndrome;  Hypothalamic and pituitary diseases
DOI:
10.3760/cma.j.cn121383-20220117-01034
摘要:
糖脂代谢紊乱是代谢综合征的重要组成部分,可增加心脑血管疾病发病风险,导致死亡率升高。下丘脑和垂体是机体内分泌系统的中枢,它们不仅在调节靶器官内分泌功能中发挥重要作用,而且还能通过多种机制维持机体糖脂代谢稳态。下丘脑疾病所致下丘脑结构受损或功能异常,直接造成血糖、血脂代谢失衡,也可能通过影响体内各种激素水平导致糖脂代谢紊乱。垂体疾病则主要通过改变体内激素水平而影响机体糖脂代谢。为了增加临床医生对下丘脑垂体疾病合并糖脂代谢紊乱的认识及管理能力,本文拟从功能性垂体瘤、垂体功能减退及下丘脑疾病对糖脂代谢的影响3个方面对该问题进行阐述。
Abstract:
Both hyperglycemia and dyslipidemia are important components of metabolic syndrome,which increase the risk and mortalities of cardiovascular and cerebrovascular diseases. The hypothalamus and pituitary are the centers of the endocrine system. They not only play critical roles in regulating the endocrine function of target organs, but also regulate glucose and lipid homeostasis by various mechanisms. Impaired structure or function of the hypothalamus by a series of diseases, could directly cause the imbalance of glucose and lipid homeostasis, or lead to this disorder by affecting the body hormones. However, pituitary diseases mainly affect glucose and lipid metabolism by changing hormone. In order to promote clinicians' understanding and management of hyperglycemia and dyslipidemia related to hypothalamic and pituitary diseases, this paper intends to elaborate this problem from three aspects: functional pituitary tumor, hypopituitarism and hypothalamic diseases.

参考文献/References:

[1] Melmed S.Pituitary-tumor endocrinopathies[J].N Engl J Med,2020,382(10):937-950.DOI:10.1056/NEJMra1810772.
[2] Auriemma RS,De Alcubierre D,Pirchio R,et al.The effects of hyperprolactinemian and its control on metabolic diseases[J].Expert Rev Endocrinol Metab,2018,13(2):99-106.DOI:10.1080/17446651.2018.1434412.
[3] Lopez-Vicchi F,De Winne C,Brie B,et al. Metabolic functions of prolactin:physiological and pathological aspects[J].J Neuroendocrinol,2020,32(11):e12888.DOI:10.1111/jne.12888.
[4] Macotela Y,Triebel J,Clapp C.Time for a new perspective on prolactin in metabolism[J]. Trends Endocrinol Metab,2020,31(4):276-286.DOI:10.1016/j.tem.2020.01.004.
[5] Pirchio R,Auriemma RS,Solari D,et al. Effects of pituitary surgery and high-dose cabergoline therapy on metabolic profile in patients with prolactinoma resistant to conventional cabergoline treatment[J].Front Endocrinol(Lausanne),2021,12:769744.DOI:10.3389/fendo.2021.769744.
[6] Auriemma RS,Granieri L,Galdiero M,et al.Effect of cabergoline on metabolisn in prolactinomas[J].Neuroendocrinology,2013,98(4):299-310.DOI:10.1159/000357810.
[7] Kasuki L,Antunes X,Lamback EB,et al.Acromegaly:update on management and long-term morbidities[J].Endocrinol Metab Clin North Am,2020,49(3):475-486.DOI:10.1016/j.ecl.2020.05.007.
[8] He W,Yan L,Wang M,et al.Surgical outcomes and predictors of glucose metabolism alterations for growth hormone-secreting pituitary adenomas:a hospital-based study of 151 cases[J].Endocrine,2019,63(1):27-35.DOI:10.1007/s12020-018-1745-7.
[9] Gadelha MR,Kasuki L,Lim DST,et al. Systemic complications of acromegaly and the impact of the current treatment landscape:an update[J].Endocr Rev,2019,40(1):268-332.DOI:10.1210/er.2018-00115.
[10] Zhang Y,Wang M,Ji C,et al. Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver[J]. iScience,2021,24(9):102983. DOI:10.1016/j.isci.2021.102983.
[11] Mazziotti G,Floriani I,Bonadonna S,et al.Effects of somatostatin analogs on glucose homeostasis:a metaanalysis of acromegaly studies[J].J Clin Endocrinol Metab,2009,94(5):1500-1508.DOI:10.1210/jc.2008-2332.
[12] Shen M,Wang M,He W,et al.Impact of long-acting somatostatin analogues on glucose metabolism in acromegaly:a hospital-based study[J].Int J Endocrinol,2018,3015854.DOI:10.1155/2018/3015854.
[13] Schmid Ha,Brue T,Colao A,et al.Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly[J].Endocrine,2016,53(1):210-219.DOI:10.1007/s12020-016-0895-8.
[14] Shao XQ,Chen ZY,Wang M,et al.Effects of long-acting somatostatin analogues on lipid metabolism in patients with newly diagnosed acromegaly:a retrospective study of 120 cases[J].Horm Metab Res,2022,54(1):25-32.DOI:10.1055/a-1717-9332.
[15] Feola T,Cozzolino A,Simonelli I,et al.Pegvisomant improves glucose metabolism in acromegaly:a meta-analysis of prospective interventional studies[J].J Clin Endocrinol Metab,2019,104(7):2892-2902.DOI:10.1210/jc.2018-02281.
[16] Mazziotti G,Gazzaruso C,Giustina A.Diabetes in cushing syndrome:basic and clinical aspects[J].Trends Endocrinol Metab,2011,22(12):499-506.DOI:10.1016/j.tem.2011.09.001.
[17] 刘心华,朱小明,何敏等.库欣病患者糖代谢异常的相关因素分析[J].中华糖尿病杂志,2019,11(7):461-465.DOI:10.3760/cma.j.issn.1674-5809.2019.07.004.
[18] Pivonello R,Isidori AM,De Martino MC,et al. Complications of cushing's syndrome:state of the art[J].Lancet Diabetes Endocrinol,2016,4(7):611-629.DOI:10.1016/S2213-8587(16)00086-3.
[19] Sacroni C,Zilio M,Foti M,et al.Glucose metabolism abnormalities in cushing's syndrome:frome molecular basis to clinical management[J].Endocr Rev,2017,38(3):189-219.DOI:10.1210/er.2016-1105.
[20] Sun X,Feng M,Lu L,et al.Lipid abnormalities in patients with cushing's disease and its relationship with impaired glucose metabolism[J].Front Endocrinol(Lausanne),2021,11:600323.DOI:10.3389/fendo.2020.600323.
[21] Miljic' D,Popovic V.Metabolic syndrome in hypopituitarism[J].Front Horm Res,2018,49:1-19. DOI:10.1159/000485997.
[22] Bhattacharya S,Kalra S,Dutta D,et al.The interplay between pituitary health and diabetes mellitus-the need for‘hypophyseo-vigilance'[J].Eur Endocrinol,2020,16(1):25-31.DOI:10.17925/EE.2020.16.1.25.
[23] Weber MM,Biller BM,Pedersen BT,et al.The effect of growth hormone(GH)replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency:real-life data from the Nordinet international outcome study[J].Clin Endocrinol(Oxf),2017,86(2):192-198.DOI:10.1111/cen.13256.
[24] Filipsson H,Monson JP,Koltowska-Häggström M,et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients[J].J Clin Endocrinol Metab,2006,91(10):3954-3961.DOI:10.1210/jc.2006-0524.
[25] Tups A,Benzler J,Sergi D,et al.Central regulation of glucose homeostasis[J].Compr Physiol,2017,7(2):741-764.DOI:10.1002/cphy.c160015.
[26] Gautier AGodbout A,Grosheny C,et al.Markers of recurrence and long-term morbidity in craniopharyngioma:a systematic analysis of 171 patients[J].J Clin Endocrinol Metab,2012,97(4):1258-1267.DOI:10.1210/jc.2011-2817.
[27] Xiang B,Sun Q,He M,et al.Successful diagnosis and remarkable metabolic disorders in patients with solitary hypothalamic mass:a case series report[J].Front Endocrinol(Lausanne),2021,12:693669.DOI:10.3389/fendo.2021.693669.

相似文献/References:

[1]曹琳,杨昱,刘超.减重手术对多囊卵巢综合征的治疗作用[J].国际内分泌代谢杂志,2014,(06):415.[doi:10.3760/cma.j.issn.1673-4157.2014.06.015]
　Cao Lin,Yang Yu,Liu Chao..Therapeutic effects of bariatric surgery on polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2014,(01):415.[doi:10.3760/cma.j.issn.1673-4157.2014.06.015]
[2]孙如琼,林少达.宫内发育迟缓与糖脂代谢异常[J].国际内分泌代谢杂志,2014,(01):25.[doi:10.3760/cma.j.issn.1673-4157.2014.01.007]
　Sun Ruqiong,Lin Shaoda.Intrauterine growth retardation and disorder of glucolipid metabolism[J].International Journal of Endocrinology and Metabolism,2014,(01):25.[doi:10.3760/cma.j.issn.1673-4157.2014.01.007]
[3]杨雪,时立新,张巧,等.中老年人群25-羟维生素D3与代谢综合征的 相关性分析[J].国际内分泌代谢杂志,2014,(05):289.[doi:10.3760/cma.j.issn.1673-4157.2014.05.001]
　Yang Xue*,Shi Lixin,Zhang Qiao,et al.Association between 25-hydroxyvitamin D3 and metabolic syndrome in middle-aged and elderly population[J].International Journal of Endocrinology and Metabolism,2014,(01):289.[doi:10.3760/cma.j.issn.1673-4157.2014.05.001]
[4]梁绮君 余寿益 李淑华 胡晨鸣 杨焱.甲状腺结节与代谢综合征的相关性研究[J].国际内分泌代谢杂志,2015,(05):293.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.002]
　Liang Qijun,Yu Shouyi,Li Shuhua,et al.Association of thyroid nodule and metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2015,(01):293.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.002]
[5]王姝洁,张翼飞,张志国.雷公藤红素在治疗代谢综合征中的作用及相关机制[J].国际内分泌代谢杂志,2017,37(04):258.
　Wang Shujie,Zhang Yifei,Zhang Zhiguo..Effects and related mechanisms of celastrol in the treatment of metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2017,37(01):258.
[6]王雪姣,丁晓颖,彭永德.短链脂肪酸在2型糖尿病发病机制中的作用[J].国际内分泌代谢杂志,2017,37(04):270.
　Wang Xuejiao,Ding Xiaoying,Peng Yongde..The role of short chain fatty acids in the pathogenesis of type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2017,37(01):270.
[7]高璐,信中,袁明霞,等.代谢综合征与糖尿病及糖尿病前期人群 糖尿病视网膜病变的相关性分析[J].国际内分泌代谢杂志,2017,37(05):298.
　Gao Lu*,Xin Zhong,Yuan Mingxia,et al.A study on correlation between metabolic syndrome and diabetic retinopathy in diabetic and pre-diabetic people[J].International Journal of Endocrinology and Metabolism,2017,37(01):298.
[8]谢幸 陈树春 朱海娇 刘阳 王幸.蛙皮素样受体亚型-3与代谢综合征[J].国际内分泌代谢杂志,2018,38(03):176.[doi:10.3760/cma.j.issn.1673-4157.2018.03.008]
　Xie Xing*,Chen Shuchun,Zhu Haijiao,et al.Bombesin receptor subtype-3 and metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2018,38(01):176.[doi:10.3760/cma.j.issn.1673-4157.2018.03.008]
[9]聂秀玲.长期果糖摄入与代谢综合征[J].国际内分泌代谢杂志,2018,38(05):339.[doi:10.3760/cma.j.issn.1673-4157.2018.05.014]
　Nie Xiuling.Chronic fructose intake and metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2018,38(01):339.[doi:10.3760/cma.j.issn.1673-4157.2018.05.014]
[10]肖扬 徐书杭 黄华英 郭玲 吕文君 冯宁霞 汪奇峰 茅晓东 陈国芳 刘超.常州地区青少年人群不同代谢综合征诊断标准的比较研究[J].国际内分泌代谢杂志,2020,40(01):1.[doi:10.3760/cma.j.issn.1673-4157.2020.01.001]
　Xiao Yang,Xu Shuhang,Huang Huaying,et al.A comparative study of the different diagnostic criteria for metabolic syndrome among adolescents in Changzhou area[J].International Journal of Endocrinology and Metabolism,2020,40(01):1.[doi:10.3760/cma.j.issn.1673-4157.2020.01.001]

备注/Memo

备注/Memo:
通信作者:李益明,Email:yimingli@fudan.edu.cn
更新日期/Last Update: 2022-01-20